10.06
Schlusskurs vom Vortag:
$10.30
Offen:
$10
24-Stunden-Volumen:
7,532
Relative Volume:
0.29
Marktkapitalisierung:
$63.58M
Einnahmen:
$28.83M
Nettoeinkommen (Verlust:
$-13.34M
KGV:
-6.6184
EPS:
-1.52
Netto-Cashflow:
$-7.49M
1W Leistung:
-12.06%
1M Leistung:
-12.90%
6M Leistung:
+246.90%
1J Leistung:
+287.67%
Exicure Inc Stock (XCUR) Company Profile
Firmenname
Exicure Inc
Sektor
Branche
Telefon
847-673-1700
Adresse
2430 N. HALSTED ST., CHICAGO, IL
Vergleichen Sie XCUR mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
0.625 | 0 | 0 | 0 | 0 | 0.00 | |
![]()
GOODO
Gladstone Commercial Corporation
|
20.79 | 372.90M | 0 | 0 | 0 | 0.00 |
![]()
JUNE
Dhandho Junoon Etf
|
11.00 | 215.29M | 0 | 0 | 0 | 0.00 |
![]()
SHMD
Schmid Group N V
|
2.87 | 149.00M | 0 | 0 | 0 | 0.00 |
![]()
PSNYW
Polestar Automotive Holding Uk
|
0.1641 | 340.19M | 2.07B | -1.42B | -1.37B | -0.6765 |
![]()
MOBBW
Mobilicom Limited Warrants
|
0.3476 | 371.47M | 0 | 0 | 0 | 0.00 |
Exicure Inc Stock (XCUR) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2021-12-13 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
2020-12-18 | Eingeleitet | BMO Capital Markets | Outperform |
2019-11-20 | Eingeleitet | Guggenheim | Buy |
Exicure Inc Aktie (XCUR) Neueste Nachrichten
Exicure Delays 10-Q Filing Amid Acquisition - TipRanks
(XCUR) Investment Analysis and Advice - news.stocktradersdaily.com
Exicure enters strategic convertible bond agreement By Investing.com - Investing.com Nigeria
Exicure Enters Convertible Bond Agreement with Subsidiary - TipRanks
Exicure enters strategic convertible bond agreement - Investing.com
Exicure concludes subject enrolment in trial of GPC-100 for multiple myeloma - Yahoo Finance
Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant | XCUR Stock News - GuruFocus
Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant - Business Wire
Geode Capital Management LLC Purchases Shares of 12,645 Exicure, Inc. (NASDAQ:XCUR) - Defense World
Exicure, Inc. (NASDAQ:XCUR) Sees Significant Drop in Short Interest - Defense World
Investors Can Still File Late Claims for Exicure $5.6M Settlement Payouts - TradingView
Why Exicure Inc. (XCUR) Soared on Monday - MSN
How To Trade (XCUR) - news.stocktradersdaily.com
10 Micro-, Small-Cap Companies Lead Monday’s Charge - Insider Monkey
Exicure, Inc. (NASDAQ:XCUR) Sees Large Drop in Short Interest - Defense World
Exicure Close to Finishing Patient Recruitment in Phase 2 Study of GPC-100 in Multiple Myeloma - MarketScreener
Exicure appoints new independent accounting firm By Investing.com - Investing.com India
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma - BioSpace
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study o - GuruFocus
Exicure appoints new independent accounting firm - Investing.com Australia
Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML) - BioSpace
How to Take Advantage of moves in (XCUR) - news.stocktradersdaily.com
Eli Lilly and Company (NYSE:LLY) and Exicure (NASDAQ:XCUR) Head to Head Analysis - Defense World
Exicure, Inc. (NASDAQ:XCUR) Sees Significant Growth in Short Interest - The AM Reporter
Short Interest in Exicure, Inc. (NASDAQ:XCUR) Grows By 58.5% - Defense World
Wednesday’s Insider Moves: Top Buys and Sells in US Stocks - Investing.com India
Wednesday’s Insider Moves: Top Buys and Sells in US Stocks By Investing.com - Investing.com UK
Trading (XCUR) With Integrated Risk Controls - news.stocktradersdaily.com
Major Investment Alert: HiTron Systems Inc. Boosts Stake in Exicure! - TipRanks
HiTron Systems acquires $8.7 million in Exicure stock By Investing.com - Investing.com Canada
HiTron Systems acquires $8.7 million in Exicure stock - Investing.com
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Exicure, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm - Business Wire
Exicure Inc Reports $9.7 Million Net Loss for Fiscal Year 2024 A - GuruFocus
Exicure Announces Presentation at Chardan’s 6th Annual Genetic Medicines Conference - Business Wire
Short Interest in Exicure, Inc. (NASDAQ:XCUR) Increases By 24.2% - Defense World
Exicure, Inc. Reports Full Year 2024 Financial Results - BioSpace
EXICURE, INC. SEC 10-K Report - TradingView
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Exicure, Inc. Investors to Secure Counsel Before Important February 11 Deadline in Securities Class Action – XCUR - Business Wire
Pre-Market Momentum: Exicure (XCUR) Shares Rise After Key Approval - Stocks Telegraph
When (XCUR) Moves Investors should Listen - Stock Traders Daily
Exicure Gets Patent in Australia for Potential Cancer Treatment Combination -March 14, 2025 at 04:32 am EDT - Marketscreener.com
Exicure secures Australian patent for cancer treatment - Investing.com Australia
Exicure, Inc. Announces Issuance Of New Patent In Australia -March 13, 2025 at 05:39 pm EDT - Marketscreener.com
Exicure announces issuance of new patent in Australia - TipRanks
Exicure secures Australian patent for cancer treatment By Investing.com - Investing.com South Africa
Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia - Business Wire
Finanzdaten der Exicure Inc-Aktie (XCUR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Exicure Inc-Aktie (XCUR) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
DGP Co., Ltd. | 10% Owner |
Sep 12 '24 |
Buy |
3.00 |
237,223 |
711,669 |
849,223 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):